MTOR and diffuse large B-cell lymphoma: In comparison, the GCB subtype DLBCL follows a “tonic” BCR signaling pathway that is antigen-independent, mediated by PI3k/AKT/mTOR pathway, and lacks NF-κB pathway activity [28].